MTOR and small cell lung carcinoma: These findings may have a high potential for near-term clinical translation as the combination of DT2216 and an FDA-approved mTOR inhibitor (such as everolimus) can be rapidly evaluated in SCLC patients, given that DT2216 is already in the phase-I clinical trial (Identifier: NCT04886622).